{"id":"NCT00298831","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)","officialTitle":"A Multicenter, Open Label, Phase IIIa Trial to Evaluate the Efficacy and Safety of Org 25969 When Used at the End of a Surgical Procedure to Reverse the Neuromuscular Block Induced by Rocuronium Following Routine Anesthesia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10-27","primaryCompletion":"2006-05-22","completion":"2006-05-22","firstPosted":"2006-03-03","resultsPosted":"2019-03-15","lastUpdate":"2019-03-27"},"enrollment":224,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia, General"],"interventions":[{"type":"DRUG","name":"Sugammadex","otherNames":["Org 25969","MK-8616"]},{"type":"DRUG","name":"Rocuronium","otherNames":[]}],"arms":[{"label":"Sugammadex","type":"EXPERIMENTAL"}],"summary":"The primary purpose of the study is to determine the time-course of recovery to a T4/T1 ratio of 0.9 within 4 minutes after 4.0 mg.kg\\^-1 Sugammadex is administered at least 15 minutes after the last administration of rocuronium in a wide range of surgical procedures and anesthetic regimens (routine use). Safety evaluation is part of the study.","primaryOutcome":{"measure":"Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.9","timeFrame":"Up to approximately 30 minutes following administration of study treatment","effectByArm":[{"arm":"Sugammadex","deltaMin":2.32,"sd":2.15}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25157214"],"seeAlso":["http://www.merck.com/clinical-trials/policies-perspectives.html"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":197},"commonTop":["Procedural pain","Nausea","Dizziness","Vomiting","Pyrexia"]}}